Actelion Ltd. CEO Jean-Paul Clozel is seeking to rebuild investor confidence in the wake of the company's year-long run-in with activist shareholder Elliott Advisors.
Earlier this year, the hedge fund tried to take control of the Swiss biotech, whose board and management it claimed were falling short of their duties to shareholders. Elliott lost its battle and now holds less than 3% of the company
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?